USD
+$0.00
(+0.00%
)At Close (As of Oct 14, 2025)
$59.11B
Market Cap
14.07
P/E Ratio
39.65
EPS
$1,016.19
52 Week High
$475.77
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $12B |
Total Revenue | $14B |
Cost Of Revenue | $2.5B |
Costof Goods And Services Sold | $2.5B |
Operating Income | $4.2B |
Selling General And Administrative | $3B |
Research And Development | $4.6B |
Operating Expenses | $7.6B |
Investment Income Net | - |
Net Interest Income | $656M |
Interest Income | $711M |
Interest Expense | $55M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $483M |
Income Before Tax | $4.8B |
Income Tax Expense | $367M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $4.4B |
Comprehensive Income Net Of Tax | - |
Ebit | $4.8B |
Ebitda | $5.3B |
Net Income | $4.4B |
Field | Value (USD) |
---|---|
Total Assets | $38B |
Total Current Assets | $19B |
Cash And Cash Equivalents At Carrying Value | $2.5B |
Cash And Short Term Investments | $2.5B |
Inventory | $3.1B |
Current Net Receivables | $6.2B |
Total Non Current Assets | $19B |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $1.1B |
Intangible Assets Excluding Goodwill | $1.1B |
Goodwill | - |
Investments | - |
Long Term Investments | $8.9B |
Short Term Investments | $6.5B |
Other Current Assets | $349M |
Other Non Current Assets | - |
Total Liabilities | $8.4B |
Total Current Liabilities | $3.9B |
Current Accounts Payable | $790M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | - |
Total Non Current Liabilities | $4.5B |
Capital Lease Obligations | $720M |
Long Term Debt | $2B |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $2.7B |
Other Current Liabilities | $2.3B |
Other Non Current Liabilities | $1.6B |
Total Shareholder Equity | $29B |
Treasury Stock | - |
Retained Earnings | $32B |
Common Stock | $100K |
Common Stock Shares Outstanding | $115M |
Field | Value (USD) |
---|---|
Operating Cashflow | $4.4B |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $483M |
Capital Expenditures | $756M |
Change In Receivables | - |
Change In Inventory | -$620M |
Profit Loss | - |
Cashflow From Investment | -$2.5B |
Cashflow From Financing | -$2.2B |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$3.6B |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $4.4B |
Field | Value (USD) |
---|---|
Gross Profit | $12B |
Total Revenue | $14B |
Cost Of Revenue | $2.5B |
Costof Goods And Services Sold | $2.5B |
Operating Income | $4.2B |
Selling General And Administrative | $3B |
Research And Development | $4.6B |
Operating Expenses | $7.6B |
Investment Income Net | - |
Net Interest Income | $656M |
Interest Income | $711M |
Interest Expense | $55M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $483M |
Income Before Tax | $4.8B |
Income Tax Expense | $367M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $4.4B |
Comprehensive Income Net Of Tax | - |
Ebit | $4.8B |
Ebitda | $5.3B |
Net Income | $4.4B |
Field | Value |
---|---|
Ex Dividend Date | 2025-08-18 |
Declaration Date | 2025-08-01 |
Record Date | 2025-08-18 |
Payment Date | 2025-09-03 |
Amount | 0.88 |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Regeneron Pharmaceuticals, Inc. is a prominent American biotechnology firm headquartered in Westchester County, New York, renowned for its pioneering research and development in monoclonal antibodies and therapeutic proteins. With a diverse portfolio that spans critical therapeutic areas such as oncology, ophthalmology, and immunology, Regeneron is celebrated for its flagship products, including Eylea and Dupixent. The company boasts a strong and innovative pipeline, reflecting its unwavering commitment to scientific excellence and its position as a major contributor to the biopharmaceutical sector, consistently delivering groundbreaking therapies to meet significant unmet medical needs.